Boston Scientific net rises on cost cuts

Mon Apr 21, 2008 11:46pm BST

[-] Text [+]

CHICAGO (Reuters) - Medical device maker Boston Scientific Corp said on Monday quarterly net earnings more than doubled, boosted by cost-reduction measures and a tax benefit.

First-quarter net income was $322 million (162 million pounds), or 21 cents a share, compared with $120 million, or 8 cents a share, a year ago.

Excluding special items, Boston Scientific earned $357 million, or 24 cents a share, compared with $262 million, or 17 cents a share, in the year-ago period.

Analysts on average had forecast 19 cents a share in the latest quarter, according to Reuters Estimates.

Net sales in the first quarter were $2.05 billion, including sales from divested businesses of $32 million, compared with $2.09 billion in the year-ago quarter, which included $135 million in sales from divested businesses.

The Natick, Massachusetts-based company said worldwide sales of its drug-releasing heart stents declined to $428 million in the first quarter from $468 million a year ago. U.S. sales of drug-eluting stents were $218 million, down from $293 million.

Boston Scientific's shares closed on Monday up 38 cents, or 3 percent, at $13.03 on the New York Stock Exchange. The stock is up 12 percent for the year to date, but off 70 percent from its mid-2004 peak.

(Reporting by Susan Kelly; editing by Carol Bishopric/Andre Grenon)

Insider sales not a sell signal

U.S. corporate bosses are likely to sell more of their companies' stock through to the end of the year, but that does not mean share prices have topped. Full Article